Company intelligence / Profile preview
Todd Pharm
- Ownership
- Private
- Development stage
- Other
Overview
TODD Pharm is a South Korean biotechnology company specializing in the structure-based design and development of protein-based and synthetic chemical therapeutics. A subsidiary of Ewha Technology Holdings, the company focuses on metabolic diseases, such as obesity and metabolic dysfunction-associated steatohepatitis (MASH), as well as multi-drug resistant bacterial infections. Its lead program, TODD-B-001, is a patented, high-affinity FGF21 variant designed for enhanced potency and thermostability, currently in preclinical development for MASH and obesity. Additionally, TODD Pharm is developing TODD-C-001, a novel beta-lactamase inhibitor aimed at overcoming antibiotic resistance in multi-drug resistant pathogens.
- Therapeutic areas
- Infectious DiseasesEndocrinologyMetabolic DisordersGastroenterology
- Modalities
- Recombinant proteinBiologicSmall molecule
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Todd Pharm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Todd Pharm.